Immunocore (IMCR)

• Market cap: $1.78B
• 1 day: -3.64%
• 5 days: -6.05%
• 1 month: 10.57%
• 3 months: -1.09%
• 6 months: 21.31%
• Year to date: 18.18%
• 1 year: 6.72%
• 5 years: -18.43%
• 10 years: -18.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Employees: 493

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

138% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 13

15% more funds holding

Funds holding: 115 [Q1] → 132 (+17) [Q2]

13% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 40

7% more capital invested

Capital invested by funds: $1.4B [Q1] → $1.5B (+$95.7M) [Q2]

0.63% more ownership

Funds ownership: 94.44% [Q1] → 95.07% (+0.63%) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

75% less call options, than puts

Call options by funds: $9.21M | Put options by funds: $36.6M